{
  "variants": [
    {
      "gene": "SNCA",
      "protein_change": "A30P",
      "variant_string_id": "SNCA A30P",
      "flowchart_steps": {
        "step_1": {
          "description": "The study investigates the role of Cu(II) binding to R-synuclein (SNCA) in Parkinson's disease (PD), with A30P and A53T mutations implicated in familial PD.",
          "satisfied": true
        },
        "step_2": {
          "description": "The study compares wild-type (WT) R-synuclein to A30P and A53T variants. No additional pathogenic/benign variants are used as controls.",
          "satisfied": false
        },
        "step_3": {
          "substeps": {
            "3a": {
              "description": "Basic controls (WT) are used, but no variant-specific controls (e.g., other known pathogenic/benign variants) are mentioned.",
              "satisfied": false
            },
            "3b": {
              "description": "No mention of assay novelty, prior validation, or commercial kits for this specific study.",
              "satisfied": false
            },
            "3c": {
              "description": "No variant controls (e.g., known pathogenic/benign variants) are used in the assay.",
              "satisfied": false
            }
          },
          "satisfied": false
        },
        "step_4": {
          "substeps": {
            "4a": {
              "description": "Statistical analyses (e.g., p-values, OddsPath) are not explicitly reported in the abstract.",
              "satisfied": false
            },
            "4b": {
              "description": "Total variant controls (other variants) used: 0 (only A30P is tested).",
              "satisfied": true
            }
          },
          "evidence_strength": "Max PS3_supporting"
        }
      }
    },
    {
      "gene": "SNCA",
      "protein_change": "A53T",
      "variant_string_id": "SNCA A53T",
      "flowchart_steps": {
        "step_1": {
          "description": "The study investigates the role of Cu(II) binding to R-synuclein (SNCA) in Parkinson's disease (PD), with A30P and A53T mutations implicated in familial PD.",
          "satisfied": true
        },
        "step_2": {
          "description": "The study compares wild-type (WT) R-synuclein to A30P and A53T variants. No additional pathogenic/benign variants are used as controls.",
          "satisfied": false
        },
        "step_3": {
          "substeps": {
            "3a": {
              "description": "Basic controls (WT) are used, but no variant-specific controls (e.g., other known pathogenic/benign variants) are mentioned.",
              "satisfied": false
            },
            "3b": {
              "description": "No mention of assay novelty, prior validation, or commercial kits for this specific study.",
              "satisfied": false
            },
            "3c": {
              "description": "No variant controls (e.g., known pathogenic/benign variants) are used in the assay.",
              "satisfied": false
            }
          },
          "satisfied": false
        },
        "step_4": {
          "substeps": {
            "4a": {
              "description": "Statistical analyses (e.g., p-values, OddsPath) are not explicitly reported in the abstract.",
              "satisfied": false
            },
            "4b": {
              "description": "Total variant controls (other variants) used: 0 (only A53T is tested).",
              "satisfied": true
            }
          },
          "evidence_strength": "Max PS3_supporting"
        }
      }
    }
  ]
}